Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Durvalumab+ Anlotinib + Standard Chemotherapy in First-line Treatment of Extensive Small-cell Lung Cancer: a Single-arm Phase II Clinical Study

NCT04660097 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT04660097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04660097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Durvalumab+ Anlotinib + Standard Chemotherapy in First-line Treatment of Extensive Small-cell Lung Cancer: a Single-arm Phase II Clinical Study
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Completed
Start date
May 20, 2021
Completion date
June 30, 2024
Enrollment
34 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

sclc, extensive stage